REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Paediatric > Paediatric Chapters > 5. Infections >

BNSSG Paediatric Joint Formulary

5.6 Viral infection

Last edited: 14-02-2024

5.6.1 Hepatitis

First line drugs Second line drugs Specialist drugs Secondary care drugs

 

5.6.2 Hepatitis B, chronic

Peginterferon alfa (parenteral) (TLS Red)

 

5.6.3 Hepatitis C, chronic

Peginterferon alfa (parenteral) (TLS Red)

  • NICE TA300 Peginterferon alfa and ribavirin for the treatment of chronic Hepatitis C in children and young people

Ribavirin (oral) (TLS Red)

  • NICE TA300 Peginterferon alfa and ribavirin for the treatment of chronic Hepatitis C in children and young people

 

5.6.4 Herpesvirus infections

Nucleoside Analogues

Aciclovir (oral) (TLS Green)

Aciclovir (parenteral) (TLS Red)

  • Secondary care restricted, see local guidelines

Alternatives:

Valaciclovir (oral) (TLS Red)

  • Restricted, see local guidelines

 

5.6.5 Herpesvirus infections, cytomegalovirus

Non-nucleoside Pyrophosphate Analogues

Foscarnet sodium (parenteral) (TLS Red)

  • Secondary care restricted, see local guidelines

 

Nucleoside Analogues

Cidofovir (parenteral) (TLS Red)

  • Secondary care restricted, see local guidelines

Ganciclovir (parenteral) (TLS Red)

  • Secondary care restricted, see local guidelines

Valganciclovir (oral) (TLS Red)

  • Secondary care restricted, see local guidelines

Valganciclovir solution (oral) (TLS Red)

  • Secondary care restricted, see local guidelines

 

5.6.6 HIV infection

HIV Fusion Inhibitors

Enfuvirtide (parenteral) (TLS Red)

 

HIV Integrase Inhibitors

Dolutegravir (oral) (TLS Red)

Abacavir / Dolutegravir / Lamivudine (oral) (TLS Red)

 

Non-nucleoside Reverse Transcriptase Inhibitors

Efavirenz (oral) (TLS Red)

Etravirine (oral) (TLS Red)

Nevirapine (oral) (TLS Red)

Rilpivirine (oral) (TLS Red)

 

Nucleoside Reverse Transcriptase Inhibitors

Abacavir (oral) (TLS Red)

Didanosine (oral) (TLS Red)

Emtricitabine (oral) (TLS Red)

Lamivudine (oral) (TLS Red)

Tenofovir disoproxil (oral) (TLS Red)

Zidovudine (oral & parenteral) (TLS Red)

 

Protease Inhibitors (HIV)

Atazanavir (oral) (TLS Red)

Darunavir (oral) (TLS Red)

Ritonavir (oral) (TLS Red)

 

5.6.7 Influenza

See NICE TA158

As per NICE TA168 Influenza (treatment)

Neuraminidase inhibitors

Oseltamivir (oral) (TLS Green)

  • Restricted, see local guidelines

Zanamivir (oral) (TLS Green)

  • Restricted, see local guidelines

Zanamivir (intravenous) (TLS Red)

  • Secondary care restricted in line with Public Health England Guidance for severe/complicated influenza (treatment), see local guidelines

 

5.6.8 Respiratory Syncytial virus

Palivizumab (parenteral) (TLS Red)

  • NHSE SSC 2616 End of 2023-24 Respiratory Syncytial Virus (RSV) season and cessation of access to palivizumab passive immunisation against RSV in at risk pre-term infants